- GSK583
-
- $46.00 / 1mg
-
2025-09-22
- CAS:1346547-00-9
- Min. Order:
- Purity: 98.68%
- Supply Ability: 10g
- GSK583
-
- $1.00 / 1ASSAYS
-
2019-09-06
- CAS:1346547-00-9
- Min. Order: 1ASSAYS
- Purity: 95%~99%
- Supply Ability: per week:100kg
|
| Product Name: | GSK583 | | Synonyms: | GSK583;SK583;6-[(1,1-Dimethylethyl)sulfonyl]-N-(5-fluoro-1H-indazol-3-yl)-4-quinolinamine;RIP2 kinase inhibitor 583;CS-2216;GSK583, >98%;GSK-583;GSK 583;4-Quinolinamine, 6-[(1,1-dimethylethyl)sulfonyl]-N-(5-fluoro-1H-indazol-3-yl)- | | CAS: | 1346547-00-9 | | MF: | C20H19FN4O2S | | MW: | 398.45 | | EINECS: | | | Product Categories: | | | Mol File: | 1346547-00-9.mol |  |
| | GSK583 Chemical Properties |
| Boiling point | 652.9±55.0 °C(Predicted) | | density | 1.402±0.06 g/cm3(Predicted) | | storage temp. | under inert gas (nitrogen or Argon) at 2–8 °C | | solubility | Soluble in DMSO (up to at least 25 mg/ml). | | form | solid | | pka | 12.59±0.40(Predicted) | | color | Pale yellow | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 1 month. | | InChI | InChI=1S/C20H19FN4O2S/c1-20(2,3)28(26,27)13-5-7-16-14(11-13)17(8-9-22-16)23-19-15-10-12(21)4-6-18(15)24-25-19/h4-11H,1-3H3,(H2,22,23,24,25) | | InChIKey | XLOGLWKOHPIJLV-UHFFFAOYSA-N | | SMILES | N1C2C(=CC(S(C(C)(C)C)(=O)=O)=CC=2)C(NC2C3=C(NN=2)C=CC(F)=C3)=CC=1 |
| | GSK583 Usage And Synthesis |
| Description | GSK583 (1346547-00-9) is a highly selective and potent inhibitor of RIP2 kinase, IC50?= 5 nM human and IC50?= 2 nM rat.1?It also potently inhibits isolated RIP3 kinase (IC50?= 5 nM) but is inactive against RIP3 in cellular assays due to a very low KM,ATP. GSK583 blocks NOD2 signaling by interfering with XIAP-RIP2 binding resulting in decreased cytokine and chemokine production.1,2 | | Uses | GSK 583, is a selective inhibitor of RIP-like interacting CLARP kinase RIP2 Kinase is a central component of the innate immune system and enables downstream signaling following activation of the pattern recognition receptors NOD1 and NOD2, leading to the production of inflammatory cytokines. | | in vivo | GSK583 (0.1, 1, and 10 mg/kg, p.o.) inhibits serum KC (the rodent orthologue of IL-8) levels in rats in a dose-dependent manner, with an IC50 derived from rat blood concentrations of 50 nM (or 20 ng/mL). Similarly, GSK583 inhibits serum KC levels and recruitment of neutrophils into the peritoneal cavity in mice in a dose-dependent manner, with an IC50 of 37 nM (15 ng/mL) derived from mouse blood concentration[1]. | | storage | Store at +4°C | | References | [1] PAMELA A. HAILE. The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase[J]. Journal of Medicinal Chemistry, 2016, 59 10: 4867-4880. DOI:10.1021/acs.jmedchem.6b00211
[2] TATIANA GONCHAROV. Disruption of XIAP-RIP2 Association Blocks NOD2-Mediated Inflammatory Signaling.[J]. Molecular Cell, 2018, 69 4: 551-565.e7. DOI:10.1016/j.molcel.2018.01.016 |
| | GSK583 Preparation Products And Raw materials |
|